Appeals court reinstates discrimination case against Ace Parking
Don Bauder 7:49 p.m., May 22
Shares of biotech Illumina are down 31.76% to $27.25 this morning (Oct. 7) and pressuring some other biotechs. The maker of DNA analysis equipment expects third quarter revenue of $235 million, down sharply from analysts' expectations of $278.3 million. One by one, analysts are revising their ratings of Illumina stock downward.
Comments
Use the comment form below to begin a discussion about this content.
Sign in to comment
Or login with:
OpenID